Clinical trials
catalyst calendar across sponsors →Studies where CDXS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional
Held by 10 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, D. E. Shaw & Co., Inc., AQR CAPITAL MANAGEMENT LLC, TWO SIGMA INVESTMENTS, LP, Man Group plc, +5 more) · FINRA short interest 2.1 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 1 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Study of the Safety and Tolerability of CDX-6114 in Healthy VolunteersNCT03797664The incidence of treatment-emergent adverse events experienced by the subjects following oral administration of CDX-6114Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: CDX-6114, Placebo | Healthy | 32 | 2019-04-12actual | 2021-08-04 |
| Safety and Tolerability of CDX-6114 in Healthy VolunteersNCT03577886The primary outcome measure of the study will be the incidence of treatment-emergent Adverse events experienced by the Subjects following oral administration of CDX-6114Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: CDX-6114, Placebo | Healthy | 32 | 2018-08-21actual | 2018-09-20 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19